NEULANDLAB - Neuland Laboratories Limited. Share Price

Management's outlook reflects cautious optimism for the upcoming quarters and FY26, emphasizing growth potential despite recent dips in performance. The company reported total income of INR 447.8 crores for Q3FY26, an 11.4% year-over-year increase. However, gross margins fell to 52.1%, from 53.2% in Q3FY25, primarily due to product mix challenges and lower contributions from high-margin products like Paliperidone.

Key forward-looking points from management include:

1. Commercial Molecules Growth: Management sees ramp-up in shipments with expectations of delivering more from commercial molecules over the next 12 to 24 months. This includes recently commercialized products and ongoing capital investments.

2. Capital Expenditure: The company has invested INR 254 crores towards capital expenditures in the first nine months of FY26, aligning with its growth plan which includes establishing a state-of-the-art R&D center.

3. Working Capital Optimization: Working capital is currently at 145 days of sales, and management aims to optimize this by reducing inventory levels and improving customer collection processes.

4. Medium-Term Prospects: The CMS business is experiencing traction with diverse customer interest, and management anticipates significant commercial outcomes in the next fiscal year.

5. Peptide Investment: Strong interest from innovators in peptide projects, with expectations to secure commercial manufacturing arrangements in FY27, highlights future growth avenues.

6. Caution with Guidance: Management refrained from giving specific earnings guidance but remains cautiously optimistic about achieving a stable EBITDA margin of 30% in the medium term. They highlighted the need to monitor various risks impacting the business, including regulatory changes and geopolitical factors.

Overall, while the current quarter's financials reflect short-term challenges, the management is focused on long-term strategic growth driven by product and customer development.

Major Questions and Answers from the Earnings Call

1. Question: "Despite having a higher CDMO share this quarter, our gross margins have moved down. Does that mean the CDMO's gross margins are lower than the prime API gross margin?"

Answer: "No, that's not the right deduction. The decline in gross margins was due to the absence of shipments from high-margin CMS products this quarter and operational issues affecting high-margin GDS products like Paliperidone. The CMS margins are generally significantly higher than the prime products, but these two factors contributed to the drop."

2. Question: "Where do we stand on the expanded capacity for a CDMO contract and the CMS project that was supposed to be commercialized soon? When should we see revenues from these?"

Answer: "The expansion for the CMS contract has been completed, and we've begun shipping smaller volumes. It will take another one or two quarters for the ramp-up to gain momentum. Regarding the newly commercialized CMS molecule, some shipments were done, but significant revenues will materialize in Q4 and next fiscal year."

3. Question: "What gives you optimism about Q4 and FY26 after an inline quarter like Q3?"

Answer: "Our ramp-up is ongoing and has been as planned. We're seeing a steady flow of new orders. While I can't provide specific guidance, I believe that the medium-term outlook remains positive as our product shipments gain traction, especially with larger values per individual shipment."

4. Question: "What impact do the recent India-EU and U.S. trade deals have on our business?"

Answer: "The EU deal may make us more attractive to European pharma by lowering their procurement costs. However, the U.S. deal doesn't have a direct benefit since tariffs on APIs have not previously affected us. It reduces some regulatory burdens, but there's still concern about U.S. securing API manufacturing domestically."

5. Question: "Can you clarify the increase in inventory and its relationship to the PAT growth? It looks like profits are coming from inventory gains."

Answer: "Our increased inventories are indeed a precursor to future revenue as we ramp up for expected sales. While it may seem that profits relate to inventory, our PAT growth defines our operational effectiveness in managing those inventory levels for future sales."

6. Question: "What is the status of our development pipeline? There seems to be stagnation in the number of commercial molecules."

Answer: "While it may appear stagnant at nine, we actively manage our pipeline, removing older molecules and adding new ones. The focus is now on quality over quantity - ensuring we engage with higher-value molecules rather than inflating our pipeline numbers."

7. Question: "How do we see the growth and margin trajectory looking forward?"

Answer: "We feel optimistic about achieving a CAGR of over 20% for the next decade, driven by our existing products and capacity expansion. Current ramp-ups will lead to improved EBITDA margins, which have the potential to return to the 30% range, stabilizing as we scale."

8. Question: "What type of conversations with innovators are we pursuing to grow our CMS business?"

Answer: "We're identifying innovative needs and seeking partnership opportunities. Recent discussions indicate a heightened demand for peptide manufacturing capabilities. Our strategic investments are aligned to capitalize on these identified gaps, putting us in a favorable position for growth."